Toxicity of hydroxyurea in the treatment of sickle cell anemia
DOI:
https://doi.org/10.33448/rsd-v11i4.26264Keywords:
Hydroxyurea; Sickle cell anemia; Fetal hemoglobin.Abstract
Sickle cell anemia is a hereditary disease, characterized by the alteration of red blood cells, making them look like a sickle, hence the name sickle cell. In Brazil, it affects about 8% of the black population, but due to the intense miscegenation historically occurred in the country, it can also be observed in white or brown people. The work was developed with the general objective of analyzing the characteristics of sickle cell anemia and the toxicity presented by hydroxyueria in its treatment. The work was elaborated through a bibliographic review in books and articles selected through searches in databases and books websites, the period of the researched material covers the works published between the years 2010 and 2019. Hydroxyurea is now one of the drugs most used in the treatment of sickle cell anemia for being able to increase the production of another type of hemoglobin, known as fetal hemoglobin (more present during the uterine life). High levels of fetal hemoglobin decrease the polymerization of defective red cells and reduce the risk of vaso-occlusion. Like any chemotherapy drug, however, hydroxyurea has adverse effects. Hydroxyurea represents the first drug option for patients experiencing moderate to severe clinical conditions. However, it is important to highlight the incidence of clinical improvement in all patients who use this drug.
References
Araújo, O. M. R. de et al. (2015). Survival and mortality among users and non-users of hydroxyurea with sickle cell disease. Revista Latino-Am. Enfermagem. 23(1), 67-73.
Araújo, F. das C. et al., (2020). Early diagnosis of sickle cell anemia: a literature review. Research, Society and Development, 9(4), e79942516. 10.33448/rsd-v9i4.2516.
Barroso, H. L. M. R. et al., (2021). Falciform Anemia: Conception of the family caregiver about the disease and its treatment in a City in Maranhão. Research, Society and Development, 10(7), e24010716450. 10.33448/rsd-v10i7.16450.
Cançado, R. D. et al., (2009). Protocolo clínico e diretrizes terapêuticas para uso de hidroxiureia na doença falciforme. Revista Brasileira Hematologia Hemoterapia. 31(5), 361-366
Carvalho, E. M. M. S. (2014). A pessoa com doença falciforme em unidade de emergência. Relatório preliminar de dissertação (mestrado em enfermagem) – Mestrado Ciências do cuidado em saúde, Universidade Federal Fluminense, Niterói.
Felix, A. A. (2009). Clinical-epidemiologic aspects and perception of pain in the sickle cell disease.86 f. Dissertação (Mestrado em Patologia Clínica) - Universidade Federal do Triângulo Mineiro, Uberaba.
Ferraz, M. H. C.; & Murrao, M. (2007). Diagnóstico laboratorial da doença falciforme em neonatos após o sexto mês de vida. Rev. Bras. Hematol. Hemoter. 29 (3) https://doi.org/10.1590/S1516-84842007000300005
Figueiredo, M. S. (2007). Agentes indutores da síntese de hemoglobina fetal. Revista Brasileira Hematologia Hemoterapia.29(3), 313-315.
Júnior, É. B. (2014). Determinantes genéticos, bioquímicos e clínicos a resposta ao uso de hidroxiureia na doença falciforme. 177 f. Tese (Doutor em Genética) - Instituto de Biociências, Letras e Ciências Exatas, Universidade Estadual Paulista “Julio de Mesquita Filho”, Campus de São José do Rio Preto, 2014.
Loggetto, S. R. et al., (1999). Alterações imunológicas em pacientes com anemia falciforme. Rev. bras. alergia imunopatol ; 22(3): 77-82.
Lorenzi, T. F. (2006). Manual de hematologia: Propedêutica e Clínica. 4ª edição. Rio de Janeiro: Editora Guanabara Koogan.
Meneghini, A. M. B.; Netto, L. (2021). Promotion of nutritional health in adolescents with falciform disease: A single case study. Research, Society and Development, 10(7), e10010715982. 10.33448/rsd-v10i7.15982.
Melo, T. R. F. (2014). Síntese e avaliação farmacológica de novos compostos híbridos úteis para tratamento das complicações da anemia falciforme. 201 f. Dissertação (Pós-graduação em Ciências Farmacêuticas) - Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista Júlio de Mesquita Filho, Araraquara, 2014.
Pallis, F. R. (2011). Avaliação funcional dos eosinófilos na anemia falciforme e o efeito do tratamento com hidroxiureia. 89 f. Dissertação (Mestrado em Ciências Médicas) - Faculdade de Ciências Médicas, Universidade de Campinas – UNICAMP, Campinas.
Pitaluga, W. V. C. (2006). Avaliação da Qualidade de Vida de Portadores de anemia falciforme. Goiânia, 118 f. Dissertação (mestrado em psicologia) – Programa de Pós-graduação Stricto Sensu, Universidade Católica de Goiás. Goiânia
Soares, E. P. B, et al., (2014). Cuidar de Pessoas com Doença Falciforme na Unidade de Emergência: discurso de uma equipe multiprofissional. Revist. Cienc. Cuid Saúde, 13(2), 278-285.
Souza, J. C. Hematologia. (2009). (26a ed.).
Sousa, É. Q. de et al., (2020). Use of hydroxyurea in sickle cell anemia: a literature review. Research, Society and Development, 9(2), e102922058, 2020. 10.33448/rsd-v9i2.2058.
Zago, M. A. (2001). Anemia falciforme e doenças falciformes. Manual de Doenças mais Importantes, por Razões Étnicas, na População Brasileira Afro-Descendente. Série A. Normas e Manuais Técnicos no Ministério da Saúde, Brasília.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Pedro Henrique Ferreira Marçal; Claudia Costa da Silva Paula; Carlos Alberto Silva; Zeina Calek Graize Trindade; Marlucy Rodrigues Lima; Michel Peçanha; Claudine de Menezes; Marileny Boechat Frauches Brandão; Leonardo Oliveira Leão e Silva; Suely Maria Rodrigues; Pedro Henrique Ferreira Marçal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
